Advertisement
Home Day 3

Day 3

Real-World Analysis of Cost Savings Related to Sacubitril-Valsartan for Heart Failure

Sacubitril-valsartan is approved by the FDA to treat heart failure with reduced ejection fraction (HFrEF). Researchers sought to determine the real-world impact...

U.S. Biosimilar Uptake: The Pharmacist’s Role in Breaking Barriers

Biosimilars face utilization uptake barriers in the U.S. market which could delay their use for years, even after approval. Managed care pharmacists...

Value-Based Payment Models That Integrate Pharmacist Involvement

Health plans can provide cost data demonstrating medication cost trends, but clinical data are required from the health system to offer a...

How to Incorporate Real-World Evidence into Oncology Care Decision-Making

Payers face significant and growing costs with oncology treatments. Real-world evidence (RWE), such as real-world observational studies, patient-reported outcomes (PROs), and economic...
Advertisement